Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:42:10 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q0.11.47·2.471.01.60-0.02-1.254.2705281.646  1.675  1.602.04  1.1317:14:49Jan 2915 min RT 2¢

Recent Trades - Last 10 of 528
Time ETExPriceChangeVolume
17:14:49Q1.6013-0.01871
16:10:04Q1.60-0.021
16:04:48Q1.60-0.021
16:04:16Q1.60-0.021
16:00:02Q1.60-0.0291
16:00:02Q1.60-0.02183
16:00:02Q1.60-0.0217
16:00:02Q1.60-0.02100
16:00:02Q1.60-0.0283
16:00:02Q1.60-0.02400

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-29 18:00U:MNOVNews ReleaseMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
2026-01-06 09:00U:MNOVNews Release2026 New Year's Greetings from the CEO
2025-12-18 06:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
2025-12-08 06:00U:MNOVNews ReleaseMediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
2025-12-01 18:00U:MNOVNews ReleaseMessage from the CEO to MediciNova Shareholders
2025-11-18 06:00U:MNOVNews ReleaseMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
2025-11-06 18:00U:MNOVNews ReleaseMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
2025-11-04 07:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2025-10-30 19:00U:MNOVNews ReleaseMediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
2025-10-06 08:00U:MNOVNews ReleaseMediciNova to Present at the LD Micro Main Event XIX Investor Conference
2025-09-22 08:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
2025-09-16 08:00U:MNOVNews ReleaseMediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
2025-09-08 09:00U:MNOVNews ReleaseMediciNova Provides Shareholder Update on Key Developments
2025-09-03 07:00U:MNOVNews ReleaseMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-26 19:00U:MNOVNews ReleaseMediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
2025-07-31 19:30U:MNOVNews ReleaseMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
2025-07-24 06:00U:MNOVNews ReleaseMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
2025-04-14 19:00U:MNOVNews ReleaseMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
2025-04-08 19:00U:MNOVNews ReleaseFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients